An expansion of the previous Decentralized Clinical Trials SIG, the Therapeutics Lifecycle Special Interest Group brings together industry and medical experts to explore and develop ways to transform access, engagement and economics across the therapeutics discovery-to-market life cycle with telehealth.

Specific areas of concentration include identifying and removing barriers to:

• Access: By improving diversity, inclusion and equity in access across the life cycle and evolving distribution & dispensing infrastructure for care anywhere.
• Engagement: By reducing loss-to-follow-up in trials & care and increasing patient therapeutic literacy and compliance.
• Economics: By increasing speed of recruitment, improving retention and increasing staff productivity, improving physician support, and reducing fraud, waste and abuse.

This Special Interest Group focused previously on the Decentralized Clinical Trials component, and now has a broader scope.

Meetings are the 4th Wednesday of the month at 3p Eastern.